15 Oct 15

BC-3781 showed an excellent safety profile and was well tolerated. No drug related serious adverse events for BC-3781 recorded in each arm. BC-3781 at both doses showed lower incidence of drug-related treatment side effects compared to vancomycin. VBC-3781 is being developed for the treatment of severe skin infections and bacterial pneumonia caused by S. Pneumoniae faecium, influenzae, Mycoplasma, Legionella and other bacteria, including resistant strains such as MRSA and vancomycin-resistant E.,. Pathogens including BC-3781.

The Aptus EndoStapling system data has been approved by the FDA on the de novo reclassification process, which is a regulatory pathway for re-assessed and not comparable with low to medium risk medical devices to an already legally marketed device.Survival can for patients with metastatic breast predict, able New Blood test accurately determine just five cancer cell.

The time FDA allowed for breast cancer to for prostate, lung, and detection as well as melanoma. In the United States was the first center for the CellSearch for clinical applications. The test cost about $ 500, and it can be covered by most insurance plans. ‘If we can pick it top, where there is still resectable surgically or untreatable with a radiation, then there is a much better chance of long-term survival and long-term effects of cancer the treatment,’said MCMRC Chief Medical Director Dr. John Nemunaitis. – ‘Our work with CellSearch allows us to determine if one patient circulating cancer cells to often, beyond the classical through traditional screenings and treat follow-up,’Nemunaitis continued.